IP Library Granted Patent US 9,993,448
Granted Patent B2
US 9,993,448 · App. 15/701,107 · Granted Jun 12, 2018

Bolus dose of hydroxycitric acid with glycerol

Inventors: Dallas L. Clouatre (Seattle, WA); Daniel E. Clouatre (Seattle, WA); Brad J. Douglass (Seattle, WA)
Assignee: GLYKON TECHNOLOGIES GROUP, LLC
A61K31/194A61J1/1412A61K9/0053A61K9/0095A61K9/14A61K9/145A61K31/00A61K31/216A61K36/185A61K36/42A61K36/74A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,993,448
App. No.
15/701,107
Granted
Jun 12, 2018
Kind
B2
Abstract

A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.

Claims (6)

1. A method consisting essentially of:

(i) creating an aqueous solution of a hydroxycitrate salt and glycerol,

(ii) wherein the glycerol is present in an amount of about 1 to 3 parts by volume and the water is present in an amount of about 3 to 1 parts by volume to create the aqueous solution, wherein the hydroxycitrate salt is present in the aqueous solution at a concentration ranging from about 1.1 to 1.7 molar dosage;

(ii) placing the aqueous solution in a sealed dosage container;

(iii) orally administering the sealed dosage container to a human or animal wherein the hydoxycitrate salt is present in an amount of 1.5 g to 4.5 g±20%, and the glycerol is present in an amount in a range of from 1.0 g to 4.0 g±20%.

2. The method of claim 1 , further consisting essentially of an active agent selected from the group consisting of a green coffee bean extract, a bitter melon extract, and sesame lignan extract.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2022
From: GLYKON TECHNOLOGIES GROUP, LLC
To: NUTRITION RESEARCH GROUP, LIMITED
Reel/Frame 058559/0645 →
ASSIGNMENT AND QUITCLAIM AND ACTION BY CONSENT OF MEMBERS OF GLYKON TECHNOLOGIES GROUP LIMITED LIABILITY COMPANY Recorded Feb 7, 2018
From: DOUGLASS, BRAD J.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 045268/0429 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2018
From: CLOUATRE, DALLAS L.; CLOUATRE, DANIEL E.; DOUGLASS, BRAD J.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 044845/0635 →
Continuity (3)
Continuation 14614201 · Feb 4, 2015
Provisional Application 62081161 · Nov 18, 2014
Related Publication 20170368008A1 · Dec 28, 2017